Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta.’ The study aims to assess the efficacy and safety of Romosozumab, a drug administered via subcutaneous injection, compared to standard bisphosphonate treatments. The primary focus is on reducing clinical fractures and improving bone mineral density in children and adolescents with Osteogenesis Imperfecta.
The study tests two interventions: Romosozumab, an experimental drug given monthly, and bisphosphonates, which are administered according to local standards. The goal is to determine which treatment is more effective in reducing fractures and improving bone density.
This interventional study is randomized with a parallel assignment and no masking, focusing on treatment as its primary purpose. Participants are divided into two groups to receive either Romosozumab or bisphosphonates over a 12-month period.
The study began on April 22, 2024, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on August 5, 2025, indicating ongoing recruitment and data collection.
For investors, this study could influence Amgen’s stock performance, especially if Romosozumab proves more effective than current treatments. Success in this study could position Amgen favorably against competitors in the osteoporosis treatment market, potentially boosting investor confidence.
The study is actively recruiting, and further details are available on the ClinicalTrials portal.